A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
KPV (lysine-proline-valine) is a tiny 3-amino-acid fragment of a larger hormone called alpha-MSH — a hormone your body already uses to regulate pigmentation, fever, and importantly, to dial down inflammation once an immune response has done its job. What makes KPV interesting is a discovery from 1989: researchers found that this small fragment alone retains the anti-inflammatory power of the full hormone, even though it’s too small to actually bind the receptors alpha-MSH normally uses.
That’s a meaningful distinction. Because KPV skips the melanocortin receptor pathway entirely, it doesn’t cause the tanning effect or appetite suppression that full alpha-MSH (or riskier compounds like Melanotan II) can cause — it appears to work by getting inside cells directly and blocking a key inflammatory signaling switch (NF-κB), reducing its activity by as much as 80% in lab models. Its small size also makes it unusually resistant to being broken down in the digestive tract, which is why you’ll see it studied in oral, injectable, and topical forms.
KPV has roughly two decades of laboratory and animal research behind it — including animal models of inflammatory bowel conditions (Crohn’s, ulcerative colitis), atopic and contact dermatitis, and mast cell activation — but as of 2026, there are no large completed human clinical trials in any of these areas. What exists in human use is built on a combination of that animal research and real-world practitioner experience, which is an honest gap worth naming even though the mechanistic research behind it is genuinely well-established.
Inflammatory signaling pathways are influenced by nutrient status broadly — omega-3 fatty acids, vitamin D, zinc, and magnesium are commonly discussed in the general nutrition literature on balanced inflammatory signaling, and are worth having in place alongside any protocol targeting this pathway.
KPV is not FDA-approved for any indication. On April 15, 2026, it was removed from the FDA’s 503A Category 2 list (a procedural step, not an approval), and it was one of four compounds reviewed by the Pharmacy Compounding Advisory Committee on July 23, 2026 (alongside BPC-157, TB-500, and MOTS-c), where FDA staff briefing materials proposed against inclusion on the list that would make compounding lawful. Its legal compounding status remains unresolved as of this writing. This page describes research findings only — it is not a claim about effects in humans and not an offer to treat any condition.
Yes in preclinical studies, but it is not proven in humans. In cell cultures and animal models, KPV reduces inflammation by inhibiting NF-κB signaling, lowering inflammatory cytokines such as TNF-α, IL-1β and IL-6, and reducing the number of inflammatory cells in the tissue.
KPV has consistent anti-inflammatory effects in animal models of colitis. There are no human trials yet, but the pathways look very promising, and we do see benefit in clinical practice.
There is not much research on this. From clinical experience, the injectable version has been the most effective.
Alpha-MSH is a 13-amino-acid peptide hormone made from the POMC precursor. KPV is exactly its last three amino acids: lysine, proline and valine (positions 11 to 13).
There are no formal safety studies, but it has been widely used without reported problems to date.
KLOW is the most common way KPV is taken. KPV adds its anti-inflammatory effect to the healing and repair support of BPC-157, TB-500 and GHK-Cu.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
